CtBP is a transcriptional co-repressor for a panel of pro-apoptotic genes. Its degradation leads to cell death independent of p53. Furthermore, knockdown of CtBP is sufficient to suppress tumorigenesis in vivo. This proposal is designed to study the mechanisms of CtBP degradation in the hope of developing novel approaches for cancer treatment.
The specific aims are to: 1) Determine whether HIPK2 regulates CtBP directly or through other kinase pathways. Phosphorylation of Ser 422 triggers CtBP for degradation. We have raised an antibody to Ser 422-phosphorylated CtBP to examine whether HIPK2 interacts with other signal pathways to phosphorylate CtBP and trigger CtBP degradation. JNK1 specifically phosphorylates Ser 422. We will investigate the involvement of this pathway in CtBP degradation. 2) Determine how phosphorylation of CtBP leads to proteasomal degradation. We will focus on the identification of E3 ligase(s) responsible for CtBP polyubiquitination and degradation. The tumor suppressor Fbw7a physically interacts with CtBP and is our first candidate. We have shown that a Ser 422 phospho-peptide blocks CtBP degradation. We will use affinity chromatography and mass spectrometry to identify proteins associated with this phospho-peptide. The interaction of the targeting proteins with the phospho-peptide will be confirmed by biochemical assays and their contribution to CtBP degradation will be examined using siRNA. 3) Identify CtBP target genes involved in transformation and apoptosis. CtBP represses many epithelial- specific and pro-apoptotic genes. Whether the genes responsible for these effects are direct CtBP targets is uncertain. We will identify CtBP targets (both protein-coding and non-coding such as microRNAs) involved in apoptosis arid transformation using Serial Analysis of Chromatin Occupancy, which combines chromatin immunoprecipitation with long SAGE. Expression of target genes involved in apoptosis and transformation will be studied in specific signaling pathways that cause CtBP degradation. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA115468-01A2
Application #
7261124
Study Section
Cancer Etiology Study Section (CE)
Program Officer
Yassin, Rihab R,
Project Start
2007-08-01
Project End
2012-05-31
Budget Start
2007-08-01
Budget End
2008-05-31
Support Year
1
Fiscal Year
2007
Total Cost
$292,600
Indirect Cost
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Deng, Hui; Li, Fulun; Li, Hong et al. (2014) CtBP1 overexpression in keratinocytes perturbs skin homeostasis. J Invest Dermatol 134:1323-1331
Deng, Hui; Liu, Jing; Deng, Yu et al. (2013) CtBP1 is expressed in melanoma and represses the transcription of p16INK4a and Brca1. J Invest Dermatol 133:1294-301
Han, Gangwen; Bian, Li; Li, Fulun et al. (2013) Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. Nat Med 19:421-8
Deng, Yu; Deng, Hui; Liu, Jing et al. (2012) Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer. Mol Carcinog 51:500-7
Deng, Yu; Deng, Hui; Bi, Feng et al. (2011) MicroRNA-137 targets carboxyl-terminal binding protein 1 in melanoma cell lines. Int J Biol Sci 7:133-7
Hoot, Kristina E; Oka, Masako; Han, Gangwen et al. (2010) HGF upregulation contributes to angiogenesis in mice with keratinocyte-specific Smad2 deletion. J Clin Invest 120:3606-16
Deng, Y; Liu, J; Han, G et al. (2010) Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1. Oncogene 29:6603-8
Xu, Jielin; Bae, Eunnyung; Zhang, Qinghong et al. (2009) Display of cell surface sites for fibronectin assembly is modulated by cell adherence to (1)F3 and C-terminal modules of fibronectin. PLoS One 4:e4113